Answers are grounded in this paper and cite their sources.
BACKGROUND: The SONIA phase 3 trial demonstrated adding cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) to first-line endocrine therapy (aromatase-inhibitor) was not superior in terms of progression-free survival after two treatment lines compared to addition to second-line (fulvestrant) in patients with hormone-receptor positive, HER2-negative advanced breast cancer. Although critical to inform decision-making, a detailed health economic evaluation of both treatment strategies is currently lacking. METHODS: We estimated the cost-effectiveness of CDK4/6i use in first- versus second-line over 5 years using patient-level data. Quality-adjusted life-years (QALYs) were estimated using EQ-5D-5L questionnaires. Hospital resource use was collected while on SONIA treatment and cancer medications until the end of follow-up. Costs are presented in 2024 Euros. Outcomes were adjusted for censoring (data cut-off 1 December 2022) and several scenario and sensitivity analyses were conducted. RESULTS: Estimated life-years were 3.509 [SE 0.075] versus 3.513 [SE 0.084]; difference -0.004, 95 % CI -0.232 to 0.223 in those receiving CDK4/6i in first- versus second-line, and QALYs were 2.694 [SE 0.068] versus 2.644 [SE 0.081]; difference 0.054, 95 % CI -0.143 to 0.250, respectively. Healthcare costs were higher among patients receiving CDK4/6i in first- versus second-line (€61,821 [SE 1423] versus €39,057 [SE 1513]; difference €22,764, 95 % CI €18,815 to €26,713). This was largely driven by higher CDK4/6i drug costs (€24,699, 95 % CI €21,833 to €27,564), with no differences in the costs of secondary care visits. The ICER was €423,408 per QALY gained. Scenario and sensitivity analyses showed similar results. CONCLUSION: Delaying CDK4/6i treatment to second-line leads to large cost savings while achieving the same patient health outcomes. TRIAL REGISTRATION: The SONIA trial was registered at ClinicalTrials.gov (NCT03425838).
No takes yet. Share an insight, caveat, or question.
Wortelboer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: